Table 1.
List of Studies Included in the Meta-Analysis and Diagnostic Characteristics According to the RUNX1 Status in the Patients with AML and de Novo non-M3 AML
| Author | RUNX1 status | Number | Age | Initial WBC | Tumor type | HR for DFS | 95% CI for DFS | HR for OS | 95% CI for OS |
|---|---|---|---|---|---|---|---|---|---|
| Tang | NA | 234 | WT: 48.0 (15-90) Mu: 62.0 (15-89) |
WT: 22430 (120-627800) Mu: 15 225 (310-258900) |
AML non-m3 | WT: 1 Mu:1.580 | Reference (0.940-2.653) | WT:1 Mu: 1.874 |
Reference (1.075-3.269) |
| Verena | WT: 831(94.1%) Mu: 53(5.9%) |
884 | WT: 48.1 (19-60) Mu: 48.2 (18-60) |
WT: 13.4(0.9-235.0) Mu: 17.6(0.2-427.0) |
AML non-m3 | WT: 1 Mut: 1.296 | Reference (0.843- 1.992) | WT:1 Mut:1.077 | Reference (0.755-1.535) |
| Jason | WT: 343(87.5%) Mu: 49(12.5%) |
392 | WT: 61 (18-83) Mu: 68 (30-81) |
WT: 28.6(0.9-450.0) Mu: 21 (0.9-434.1) |
AML non-m3 | WT: 1 Mu: 2.34 |
Reference (1.49-3.66) | WT:1 Mut:1.65 | Reference (1.13-2.42) |
| Greif | NA | 71 | WT: 54 (27-83) Mu: 73 (54-78) |
WT: 39.5 (0.1-486.0) Mu: 11.70 (1.8-105.3) |
AML non-m3 | NA | NA | WT:1 Mu: 2.51 |
Reference (1.1-5.8) |
CI, confidence interval; HR, hazard ratio; DFS, disease free survival; Mu, mutant; NA, not available; OS, overall survival; WBC, white blood count; WT, wild type.